<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811053</url>
  </required_header>
  <id_info>
    <org_study_id>HR021618-203</org_study_id>
    <nct_id>NCT04811053</nct_id>
  </id_info>
  <brief_title>HR021618 in Moderate to Severe Pain After Abdominal Surgery</brief_title>
  <official_title>A Phase â…¡, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HR021618 in the Treatment of Moderate to Severe Pain After Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of HR021618 in the treatment&#xD;
      of moderate to severe pain after abdominal surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC48</measure>
    <time_frame>48 hours after recovery from anesthesia] Area under the pain intensity-time curve.</time_frame>
    <description>Area under the pain intensity-time curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total consumption of morphine over 0-48, 0-24, 24-48 hours</measure>
    <time_frame>48 hours after recovery from anesthesia</time_frame>
    <description>Total consumption of morphine after recovery from anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC3, AUC24, AUC15-21, AUC18-24, AUC24-28, AUC39-45, AUC42-48</measure>
    <time_frame>48 hours after recovery from anesthesia</time_frame>
    <description>Area under the pain intensity-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the first dose of rescue analgesia</measure>
    <time_frame>48 hours after recovery from anesthesia</time_frame>
    <description>Time of the first dose of rescue analgesia after recovery from anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects receiving rescue analgesia</measure>
    <time_frame>48 hours after recovery from anesthesia</time_frame>
    <description>Proportion of subjects receiving rescue analgesia after recovery from anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of doses of rescue analgesia</measure>
    <time_frame>48 hours after recovery from anesthesia</time_frame>
    <description>Frequency of doses of rescue analgesia after recovery from anesthesia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects' satisfaction rating</measure>
    <time_frame>48 hours after recovery from anesthesia</time_frame>
    <description>Subjects' satisfaction rating.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthesiologist satisfaction rating</measure>
    <time_frame>48 hours after recovery from anesthesia</time_frame>
    <description>Anesthesiologist satisfaction rating.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pain After Abdominal Surgery</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR021618</intervention_name>
    <description>Treatment group A: HR021618 injection</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment group B: Saline injection</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Subjects requiring elective general anesthesia abdominal surgery&#xD;
&#xD;
          3. Male or female&#xD;
&#xD;
          4. Meet BMI standard&#xD;
&#xD;
          5. Conform to the ASA Physical Status Classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a history of abdominal surgery&#xD;
&#xD;
          2. Subjects had hemorrhagic disorders&#xD;
&#xD;
          3. Subjects had cardiac, serious hepatic or renal, cardiovascular or cerebrovascular,&#xD;
             metabolic, psychiatric disorders, chronic pain, or malignant tumors&#xD;
&#xD;
          4. Subjects with poor blood pressure control after medication&#xD;
&#xD;
          5. Abnormal QTc&#xD;
&#xD;
          6. Abnormal random blood glucose&#xD;
&#xD;
          7. Abnormal values in the laboratory&#xD;
&#xD;
          8. Allergic to meloxicam or any excipient of HR021618, aspirin, other non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) or to any peri- or postoperative medications used in&#xD;
             this study&#xD;
&#xD;
          9. Use other drugs that affect the analgesic effect before randomization, and the time&#xD;
             from the last use to randomization is shorter than 5 half-lives&#xD;
&#xD;
         10. Pregnant or nursing women&#xD;
&#xD;
         11. No birth control during the specified period of time&#xD;
&#xD;
         12. Participated in clinical trials of other drugs (received experimental drugs)&#xD;
&#xD;
         13. The inestigators determined that other conditions were inappropriate for participation&#xD;
             in this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

